Abstract
Commonly, protein-based drugs are referred as therapeutic proteins. However, the term was first used to the biologics that are genetically engineered version of naturally occurring human proteins. Therapeutic proteins are large molecules consisting of long chain amino acids with multi-folded structural entity responsible for variety of biological functions. Therapeutic proteins can be clinically used in replacing an abnormally behaved protein responsible for a specific disease. They can also be supplemented with body’s supply of a beneficial protein to minimize the impact of diseases or chemotherapy. The genetically engineered proteins are approximately similar to natural proteins, and their functional efficacy can be increased by conjugating with glycans or unnatural amino acids.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17:638–642
Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: summary and pharmacological classification. Nat Rev Drug Discov 7:21–39
Walker LC, LeVine H (2000) The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 21(1–2):83–95
Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL (2001) Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 100(12):4242
Akash MSH, Rehman K, Chen S (2013) IL-1Ra and its delivery strategies: inserting the association in perspective. Pharm Res 30:2951–2966
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288:2827–2835
van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL (2004) Long term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39:804–810
Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324:1186–1194
Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P (1997) J Bone Joint Surg Am 79:326–333
Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal. J Clin Oncol 22(7):1201–1208
Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062–1068
Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J (2004) Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol 31:649–654
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N et al (2002) Randomized controlled trial of yttrium-90-labeledibritumomab tiuxetan radioimmunotherapy versus rituximab immuno therapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463
Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G (2000) Multicenter ProstaScint imaging findings in 2154patients with prostate cancer. The ProstaScint Imaging Centers. Urology 56:988–993
Campos-Neto A, Rodrigues-Junior V, Pedral-Sampaio DB, Netto EM, Ovendale PJ, Coler RN, Skeiky YA, Badaro R, Reed SG (2001) Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux test. Tuberculosis 81:353–358
Prakash PJ, Poorani E, Anantharaman P, Balasubramaniam T (2009) L-Glutaminase production and the growth of marine bacteria. Res J Microbiol 4:168–172
Sato D, Nozaki T (2009) Methionine gamma-lyase: the unique reaction mechanism, physiological roles, and therapeutic applications against infectious diseases and cancers. IUBMB Life 61:1019–1028
Ebrahiminezhad A, Rasoul-Amini S, Ghasemi Y (2011) l-Asparaginase production by moderate halophilic bacteria isolated from Maharloo salt lake. Indian J Microbiol 51:307–311
Sharma B, Singh S, Kanwar SS (2014) L-methionase: a therapeutic enzyme to treat malignancies. Biomed Res Int 2014:506287
ResearchAndMarkets.com (2020) Protein therapeutics market: global industry trends, share, size, growth, opportunity and forecast 2020-2025
Deer JR, Allison DS (2004) High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1 alpha gene. Biotechnol Prog 20:880–889
Chan KK, Wu SM, Nissom PM, Oh SK, Choo AB (2008) Generation of high-level stable transgene expressing human embryonic stem cell lines using Chinese hamster elongation factor-1 alpha promoter system. Stem Cells Dev 17:825–836
Ho SC, Mariati Y, Fang SG, Yang Y (2015) Impact of using different promoters and matrix attachment regions on recombinant protein expression level and stability in stably transfected CHO cells. Mol Biotechnol 57:138–144
Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH (2001) High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 4:75–82
Sladitschek HL, Neveu PA (2016) Bidirectional promoter engineering for single cell MicroRNA sensors in embryonic stem cells. PLoS One 11:e0155177
Seo HW et al (2010) Evaluation of combinatorial cis-regulatory elements for stable gene expression in chicken cells. BMC Biotechnol 19(10):69
Schlabach MR, Hu JK, Li M, Elledge SJ (2010) Synthetic design of strong promoters. Proc Natl Acad Sci U S A 107:2538–2543
Kim JM, Kim JS, Park DH, Kang HS, Yoon J, Baek K, Yoon Y (2004) Improved recombinant gene expression in CHO cells using matrix attachment regions. J Biotechnol 107(2):95–105
Zahn-Zabal M, Kobr M, Girod PA, Imhof M, Chatellard P, de Jesus M, Wurm F, Mermod N (2001) Development of stable cell lines for production or regulated expression using matrix attachment regions. J Biotechnol 87(1):29–42
Campbell M, Corisdeo S, McGee C, Kraichely D (2010) Utilization of site-specific recombination for generating therapeutic protein producing cell lines. Mol Biotechnol 45(3):199–202
Kennard ML, Goosney DL, Monteith D, Zhang L, Moffat M, Fischer D, Mott J (2009) The generation of stable, high MAb expressing CHO cell lines based on the artificial chromosome expression (ACE) technology. Biotechnol Bioeng 104:540–553
Shizuya H, Birren B, Kim UJ, Mancino V, Slepak T, Tachiiri Y, Simon M (1992) Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A 89:8794–8797
Monaco AP, Larin Z (1994) YACs, BACs, PACs and MACs: artificial chromosomes as research tools. Trends Biotechnol 12:280–286
Kazuki Y, Oshimura M (2011) Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther 19:1591–1601
Ioannou PA, Amemiya CT, Garnes J, Kroisel PM, Shizuya H, Chen C, Batzer MA, de Jong PJ (1994) A new bacteriophage P1-derived vector for the propagation of large human DNA fragments. Nat Genet 6:84–89
Kichler A (2004) Gene transfer with modified polyethylenimines. J Gene Med 6(Suppl 1):S3–S10
Mehier-Humbert S, Guy RH (2005) Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev 57(5):733–753
Scherer F, Anton M, Schillinger U, Henke J, Bergemann C et al (2002) Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 9(2):102–109
Wong TK, Neumann E (1982) Electric field mediated gene transfer. Biochem Biophys Res Commun 107(2):584–587
Kunert R, Reinhart D (2016) Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol 100:3451–3461
Kuo CC et al (2018) The emerging role of systems biology for engineering protein production in CHO cells. Curr Opin Biotechnol 51:64–69
Cockett MI, Bebbington CR, Yarranton GT (1990) High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology 8:662–667
Jun SC, Kim MS, Hong HJ, Lee GM (2006) Limitations to the development of humanized antibody producing Chinese hamster ovary cells using glutamine synthetase-mediated gene amplification. Biotechnol Prog 22:770–780
Tanaka SS, Mitsuda SH, Shimizu N (2014) How a replication origin and matrix attachment region accelerate gene amplification under replication stress in mammalian cells. PLoS One 9:e103439. https://doi.org/10.1371/journal.pone.0103439
Araki Y, Hamafuji T, Noguchi C, Shimizu N (2012) Efficient recombinant production in mammalian cells using a novel IR/MAR gene amplification method. PLoS One 7:e41787. https://doi.org/10.1371/journal.pone.0041787
Noguchi C, Araki Y, Miki D, Shimizu N (2012) Fusion of the Dhfr/Mtx and IR/MAR gene amplification methods produces a rapid and efficient method for stable recombinant protein production. PLoS One 7:e52990. https://doi.org/10.1371/journal.pone.0052990
Yoshimura H et al (2001) High levels of human recombinant cyclooxygenase-1 expression in mammalian cells using a novel gene amplification method. Protein Expr Purif 80:41–46
Shimizu N, Hanada N, Utani K, Sekiguchi N (2007) Interconversion of intra- and extra-chromosomal sites of gene amplification by modulation of gene expression and DNA methylation. J Cell Biochem 102:515–529
Kennard ML et al (2009) Auditioning of CHO host cell lines using the artificial chromosome expression (ACE) technology. Biotechnol Bioeng 104:526–539
Batra A et al (1986) The expression of a nopaline synthase - human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol Biol 6(5):347–357
Mason HS et al (1992) Expression of hepatitis B surface antigen in transgenic plants. PNAS 89(24):11745–11749
Boothe J, Nykiforuk C, Shen Y, Zaplachinski S, Szarka S, Kuhlman P, Murray E, Morck D, Moloney MM (2010) Seed-based expression systems for plant molecular farming. Plant Biotechnol J 8:588–606
Sack M et al (2015) (2015) From gene to harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants. Plant Biotechnol J 13(8):1094–1105
Abiri R et al (2016) Critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming. Curr Issues Mol Biol 18:21–42
Gomord V et al (2004) Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge. Plant Biotechnol J 2:83–100
Ullrich KK, Hiss M, Rensing SA (2015) Means to optimize protein expression in transgenic plants. Curr Opin Biotechnol 32:61–67
Fischer R, Emans N (2009) Molecular farming of pharmaceutical proteins. Transgenic Res 9:279–299
Franconi R, Demurtas OC, Massa S (2010) Plant-derived vaccines and other therapeutics produced in contained systems. Expert Rev Vaccines 9(8):877–892
Decker EL, Reski R (2007) Moss bioreactors producing improved biopharmaceuticals. Curr Opin Biotechnol 18:393–398
Kamenarova K et al (2005) Molecular faming in plants: an approach of agricultural biotechnology. J Cell Mol Biol 4:77–86
Hernandez R (2016) Scaling up Progressive Expression Systems. BioPharm Int 29(6):28
Sparrow PAC et al (2007) Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals. Transgenic Res 16(2):147–161
Gerlach JQ et al (2010) Plant-produced biopharmaceuticals. In: Kole C et al (eds) Transgenic crop plants. Springer, Heidelberg, pp 269–299
Desai PN et al (2010) Production of heterologous proteins in plants: strategies for optimal expression. Biotechnol Adv 28:427–435
Twyman RM et al (2003) Molecular farming in plants: host system and expression technology. Trends Biotechnol 21:570–578
Gomord V, Faye L (2004) Post-translational modification of therapeutic proteins in plants. Curr Opin Plant Biol 7:171–181
Schillberg S, Twyman RM (2007) Pharma-Planta: recombinant pharmaceuticals from plants for human health. In: Engelhard M, Hagen K, Thiele F (eds) Pharming, a new branch of biotechnology. Europäische Akademie, Berlin, pp 13–31
Franken E et al (1997) Recombinant proteins from transgenic plants. Curr Opin Biotechnol 8:411–416
Daniell H et al (2001) Medical molecular farming: production of antibodies, bio-pharmaceuticals and edible vaccines in plants. Trends Plant Sci 6:219–226
Seeliger MA et al (2003) Cooperative organization in a macromolecular complex. Nat Struct Biol 10(9):718–724
Peters T (1995) All about albumin: biochemistry, genetics, and medical applications. Academic, San Diego
Alexander MR et al (1979) Therapeutic use of albumin. JAMA 241:2527–2529
Hastings GE, Wolf PG (1992) The therapeutic use of albumin. Arch Fam Med 1:281–287
Marth E, Kleinhappl B (2001) Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine 20:532–537
Tsuchida E et al (2009) Artificial oxygen carriers, haemoglobin vesicles and albumin-hemes, based on bioconjugate chemistry. Bioconjug Chem 20:1419–1440
Zhang W et al (2006) Spread of HIV in one village in central China with a high prevalence rate of blood-borne AIDS. Int J Infect Dis 10:475–480
Farran I et al (2002) Targeted expression of human serum albumin to potato tubers. Transgenic Res 11:337–346
Huang LF et al (2005) Production of human serum albumin by sugar starvation induced promoter and rice cell culture. Transgenic Res 14:569–581
Lau OS, Sun SS (2009) Plant seeds as bioreactors for recombinant protein production. Biotechnol Adv 27:1015–1022
Yang H et al (2011) Large-scale production of functional human serum albumin from transgenic rice seeds. Proc Natl Acad Sci U S A 22:108
Balunas MJ et al (2006) Relationships between inhibitory activity against a cancer cell line panel, profiles of plants collected, and compound classes isolated in an anticancer drug discovery project. Chem Biodivers 3(8):897–915
Arijit M (2014) A novel extraction of trichosanthin from Trichosanthes kirilowii roots using three-phase partitioning and its in vitro anticancer activity. Pharm Biol 52(6):677–680
Fang EF et al (2011) Recent progress in medicinal investigations on trichosanthin and other ribosome inactivating proteins from the plant genus trichosanthes. Curr Med Chem 18(28):4410–4417
Shaw PC et al (2005) Recent advances in trichosanthin, a ribosome-inactivating protein with multiple pharmacological properties. Toxicon 45(6):683–689
Yusibov V et al (1999) Plant viral vectors based on tobamoviruses. Curr Top Microbiol Immunol 240:81–94
Rybicki EP (2009) Plant-produced vaccines: promise and reality. Drug Discov Today 14:16–24
Le DHT, Hu H, Commandeur U, Steinmetz NF (2017) Chemical addressability of potato virus X for its applications in bio/nanotechnology. J Struct Biol 200:360–368
Peruzzi PP, Chiocca EA (2016) Cancer immunotherapy: a vaccine from plant virus proteins. Nat Nanotechnol 11:214–215
Jobsri J, Allen A, Rajagopal D, Shipton M, Kanyuka K, Lomonossoff GP, Ottensmeier C, Diebold SS, Stevenson FK, Savelyeva N (2015) Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. PLoS ONE 10:e0118096
Bruckman LN (2014) Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology 449:163–173
Nester EW et al (1984) Crown gall: a molecular and physiological analysis. Annu Rev Plant Physiol 35:387–413
Binns, Thomashow (1988) Cell biology of agrobacterium infection and transformation of plants. Annu Rev Microbiol 42:575–606
Scott SE, Wilkinson MJ (1999) Low probability of chloroplast movement from oilseed rape (Brassica napus) into wild Brassica rapa. Nat Biotechnol 17:390–392
Daniell H et al (1998) Containment of herbicide resistance through genetic engineering of the chloroplast genome. Nat Biotechnol 16:345–348
De Cosa B et al (2001) Overexpression of the Bt Cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnol 19:71–74
Daniell H et al (2001) Marker free transgenic plants: engineering the chloroplast genome without the use of antibiotic selection. Curr Genet 39:109–116
Daniell H et al (2001) Antibiotic free chloroplast genetic engineering – an environmentally friendly approach. Trends Plant Sci 6:237–239
Daniell H et al (2001c) Expression of cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J Mol Biol 311:1001–1009
Staub JM et al (2000) High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 18:333–338
Rogers KK (2003) The potential of plant-made pharmaceuticals. http://www.plantpharma.org/ials/index
Kirk DD et al (2005) Risk analysis for plant-made vaccines. Transgenic Res 14:449–462
Goldstein DA, Thomas JA (2004) Biopharmaceuticals derived from genetically modified plants. QJM 97:705–716
Food and Drug Administration (2002) Pharmaceutical current good manufacturing practices (cGMPs) for the 21st century – A risk-based approach
Food and Drug Administration (2003) Pharmaceutical cGMPs for the 21st century. A risk based approach: second progress report and implementation plan
Patricia VA (2007) Available on http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=469915
Yu LX, Amidon G, Khan MA et al (2014) Understanding pharmaceutical quality by design. AAPS J 16(4):771–783
Miller RW (2001) Process analytical technologies (PAT) – part 2. Am Pharm Rev 6:1
Miller RW (2002) Process analytical technologies (PAT)- part 1. Am Pharm Rev 5:1
Arrivo SM (2003) The role of PAT in pharmaceutical research and development. Am Pharm Rev 6:2
Food and Drug Administration (2004) Guidance for industry: PAT-A framework for innovative pharmaceutical development. Manufacturing, and Quality Assurance, Rockville
Diehl B, Grout B (2011) NIR spectroscopy - just one of many analytical tools for PAT. Am Pharm Rev 3:70–74
Howard W, Ward II, Sekulic SS, Wheeler MJ, Taber G, Urbanski FJ, Sistare FE, Norris T, Aldridge PK (1998) On-line determination of reaction completion in a closed-loop hydrogenator using NIR spectroscopy. Appl Spectrosc 52(1):17–21
Santangelo M, Maranzano B, Norris K, McDermott T (2010) Near infrared (nir) determination of uniformity for a drug product powder for oral suspension (POS) in Amber Glass Bottles. Am Pharm Rev 2010:68–72
Bell M (2010) NIR as an in-process tool. Am Pharm Rev 11(3):75–79
Mattrey FT, Dolman S, Nyrop J, Skrdla PJ (2011) On-line FTIR monitoring and simultaneous optimization of a strecker reaction performed in a laboratory scale flow-through reactor. Am Pharm Rev 14:7
Sparen A, Johansson J, Svensson O, Folestad S, Claybourn M (2009) Transmission Raman spectroscopy for quantitative analysis of pharmaceutical solids. Am Pharm Rev 2009:62–73
Robbe CL et al (2003) Exploring pharmaceutical applications of near-infrared technology. Am Pharm Rev 6:3
Goode J (2004) The on-line analysis of aqueous based products from a separation column using near infrared spectroscopy. IFPAC 2004 Meeting
Skibsted E, Lindemann C, Roca C, Olsson L (2001) Online bioprocess monitoring with a multi-wavelength fluorescence sensor using multivariate calibration. J Biotechnol 88:47–57
Ge X, Tolosa L, Simpson J, Rao G (2003) Genetically engineered binding proteins as biosensors for fermentation and cell culture. Biotechnol Bioeng 84:723–731
Foster KR, Schwan HP (1986) Dielectric properties of tissues. In: Polk C, Postorv E (eds) CRC handbook of biological effects of electromagnetic fields. CRC Press, Boca Raton, pp 27–95
Davey CL, Kell DB (1995) The low-frequency dielectric properties of biological cells. In: Walz D, Berg H, Milazzo G (eds) Bioelectrochemistry of cells and tissues. Birkhauser, Basel, pp 159–207
Maca HW, Barney M, Goetzke G, Daniels D, Ryder D (1994) The use of radio frequency capacitance for the measurement of yeast viable biomass and its use in the automatic pitching of fermentations. MBAA Tech Quart 31:146–148
Carvell J, Dowd JE (2006) On-line measurements and control of viable cell density in cell culture manufacturing processes using radio-frequency impedance. Cytotechnology 50(1–3):35–48
Larson T, Gawlitzek M, Evans H, Albers U, Cacia J (2002) Chemometric evaluation of on-line high pressure liquid chromatography in mammalian cell cultures: analysis of amino acids and glucose. Biotechnol Bioeng 77:553–563
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Bahera, B.K., Prasad, R., Behera, S. (2021). Therapeutic Proteins: Production and Delivery. In: Life Sciences Industry. New Paradigms of Living Systems, vol 2. Springer, Singapore. https://doi.org/10.1007/978-981-16-2051-5_5
Download citation
DOI: https://doi.org/10.1007/978-981-16-2051-5_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-2050-8
Online ISBN: 978-981-16-2051-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)